Equillium price target lowered to $5.50 from $20 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Equillium to $5.50 from $20 and keeps a Buy rating on the shares. The target reduction is based on the elimination of future itolizumab sales from the model, the analyst tells investors in a research note.